Takeda announces positive topline results from phase 2b study evaluating tak-279, a highly selective oral tyk2 inhibitor, for the treatment of active psoriatic arthritis

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose phase 2b trial evaluating tak-279, an investigational oral allosteric tyrosine kinase 2 (tyk2) inhibitor with next generation selectivity, in people with active psoriatic arthritis. the study met its primary endpoint with a greater proportion of patients treated once-daily with tak-279 achieving at least a 20 p.
TAK Ratings Summary
TAK Quant Ranking